Home/Filings/4/0001628280-21-000061
4//SEC Filing

Kelemen Vicki 4

Accession 0001628280-21-000061

CIK 0001213037other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 4:04 PM ET

Size

9.3 KB

Accession

0001628280-21-000061

Insider Transaction Report

Form 4
Period: 2021-01-02
Kelemen Vicki
Exec. VP and COO
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2021-01-02700 total
    Common Stock (70 underlying)
  • Tax Payment

    Common Stock

    2021-01-02315,093 total
  • Exercise/Conversion

    Common Stock

    2021-01-02+705,124 total
Footnotes (4)
  • [F1]Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 3 filed with the Securities and Exchange Commission on June 22, 2020.
  • [F2]The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 31 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021.
  • [F3]Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock.
  • [F4]On January 4, 2017, the reporting person was granted 278 restricted stock units, 70 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4.

Issuer

Cardiff Oncology, Inc.

CIK 0001213037

Entity typeother

Related Parties

1
  • filerCIK 0001815809

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:04 PM ET
Size
9.3 KB